KYOWA-KIRIN
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) and a Japan-based global specialty pharmaceutical company, announced today the signing of a Promotion and Distribution Agreement with NewBridge Pharmaceuticals for the distribution of its existing rare disease portfolio across the Middle East and North Africa (MENA).
Under the terms of the agreement, NewBridge will commercialise CRYSVITA® (burosumab) for the treatment of X-Linked Hypophosphataemia (XLH) and Tumour-Induced Osteomalacia (TIO), as well as POTELIGEO® (mogamulizumab) for two subtypes of cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin’s lymphoma.
As part of the agreement, NewBridge will exclusively distribute the two products across MENA countries of Algeria, Iraq, Libya and Jordan. KKI and NewBridge also hope to collaboratively address a number of challenges facing the rare disease community in the region by supporting disease awareness, improving time to diagnosis, and improving access to innovative treatments indicated for rare and orphan diseases.
Jeremy Morgan, President of KKI, commented: “At Kyowa Kirin our purpose is to deliver life-changing medicines and make people smile. We are pleased to be entering into this agreement with NewBridge Pharmaceuticals who have a clear mission to transform the lives of MENA patients and their families. With a commitment to delivering life changing value for people impacted by under-diagnosed and under-served diseases, this agreement is key to ensuring patients living with XLH, TIO and CTCL are able to access the medicines they need, and is another positive step on our journey.”
"Given the high prevalence of rare diseases in the MENA region, I am personally inspired and proud that we at NewBridge are building on our existing partnership with Kyowa Kirin with the addition of their rare disease products to our region,” added Joe Henein, President & CEO of NewBridge Pharmaceuticals. “This collaboration totally aligns with our mission to provide access to new therapies for patients, aiming to alleviate their suffering and enhancing their quality of life."
About CRYSVITA (burosumab)
CRYSVITA (burosumab) is a recombinant human monoclonal antibody (mAb) that binds to the protein fibroblast growth factor 23 (FGF23). This has the impact of inhibiting the action of FGF23, allowing phosphate regulation in the body to be restored.1
About POTELIGEO (mogamulizumab)
Mogamulizumab is a first-in-class humanised mAb directed against CC chemokine receptor 4 (CCR4), a protein consistently expressed in both mycosis fungoides and Sézary syndrome2–4 once mogamulizumab binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells.5
About Kyowa Kirin
Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by severe and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions—Japan, Asia Pacific, North America, and EMEA/International.
You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com
About NewBridge Pharmaceuticals
NewBridge Pharmaceuticals is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialise innovative therapeutics that address unmet medical needs into the Middle East and North Africa (MENA) regions.
For more information, please visit www.nbpharma.com
References
1Electronic Medicines Compendium. Crysvita 10 mg solution for injection. Available from: https://www.medicines.org.uk/emc/product/9779/smpc#gref. Last accessed: November 2023.
2Ferenczi K, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119:1405–10.
3Yoshie O, et al. Frequent Expression of CCR4 in Adult T-Cell Leukemia and Human T-cell Leukemia Virus Type 1-transformed T cells. Blood. 2002;99(5):1505–11.
4Ishida T, et al. Clinical Significance of CCR4 Expression in Adult T-cell Leukemia/Lymphoma: Its Close Association With Skin Involvement and Unfavorable Outcome. Clin Cancer Res. 2003;9:3625–34.
5Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171–174.
KKI/INT/KKI/0959
Date of preparation: July 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807411936/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Energy Vault Secures Swiss Market Entry with Signed B-VAULT™ Deployment Contracts for Schindler and Energie Wettingen Projects, Launch of FlexGrid Product for Urban and Utility Applications4.12.2025 15:20:00 CET | Press release
Energy Vault signs two B-VAULT™ contracts in the Swiss market for projects with Schindler Aufzüge AG and Energie Wettingen, marking the launch of Energy Vault’s B-Vault™ FlexGrid program designed for commercial and industrial (C&I) customersSwitzerland is a cornerstone of Energy Vault’s European strategy, with the company moving decisively to expand its presence with multiple projects per year as part of a broader European growth strategyIntegration with CKW’s Flexpool flexibility market set to enable participation in frequency regulation, voltage control, and reactive power marketsThe Schindler FlexGrid-enabled B-VAULT system is operating and qualified by Swissgrid Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault" or the "Company"), a global leader in grid-scale energy storage solutions, today announced its formal entry into the Swiss market with the launch of FlexGrid, a product designed for C&I customers based on a new configuration of its B-VAULT battery energy storage syste
MSCI Launches Breakthrough Index Integrating Public Markets and Private Equity4.12.2025 15:00:00 CET | Press release
Innovative index is designed to provide a broad and daily view of the global equity opportunity MSCI Inc. (NYSE: MSCI) launched the MSCI All Country Public + Private Equity Index,an innovative daily index that combines public markets and a broad private equity view within a single, coherent framework. The launch marks a major shift in how investors can assess total equity exposures and measure performance across their portfolio. With private markets increasingly integrated into investment portfolios, private equity is becoming a core component of total portfolio allocation, contributing to diversification, long-term return potential and exposure to segments of the economy not captured by public markets. Reflecting the evolving structure of investor portfolios, this index sets a new standard for tracking global equity performance across public and private markets. The index combines the flagship MSCI ACWI IMI, which represents the performance of the full opportunity set of publicly list
University of Maryland Launches Innovative Clinician Training Program in Ketogenic Metabolic Therapy for Mental Health4.12.2025 15:00:00 CET | Press release
Funding from Baszucki Group fuels program for healthcare professionals to learn by doing. Baszucki Group today announced a partnership with University of Maryland School of Medicine for an innovative training initiative that will build capacity for delivering ketogenic metabolic therapy in mental health care. The program, titled “LIVE IT~LAUNCH IT: Learning How to Implement and Use a Ketogenic Diet to Improve Mental Health in Your Patients For Health Care Workers” is led by Deanna Kelly, PharmD, BCPP, the Dr. William and Carol Carpenter Professor in Psychiatry for Mental Illness Research and Director of the Maryland Psychiatric Research Center at the University of Maryland School of Medicine. This initiative aims to educate and empower practitioners by guiding them in adopting the intervention themselves. The aim is to prepare a variety of healthcare professionals to safely and confidently incorporate this promising personalized metabolic treatment framework in both clinical and resear
I-care Group Continues Global Expansion with a European Training Arm4.12.2025 15:00:00 CET | Press release
Technical Associates of Europe builds on 60+ years of training excellence I-care Group, the global leader in predictive maintenance and reliability solutions, announces the launch of Technical Associates of Europe (TAE), a new independent and certifying training organization headquartered in Mons, Belgium. This strategic initiative strengthens I-care’s global development and extends its professional training offerings in maintenance, reliability, lubrication and predictive-maintenance technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204628319/en/ Building on the heritage of Technical Associates of Charlotte (TAC) — a U.S. training organization founded in 1961 and acquired by I-care Group in 2023 —Technical Associates of Europe represents a major expansion of I-care’s training ecosystem. “Technical Associates of Europe marks an important milestone in I-care’s journey,” said Fabrice Brion, CEO of I-care Group. “
Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds4.12.2025 14:30:00 CET | Press release
79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns92% of LPs say specialist outsourcing enhances transparency Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals. Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1 While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sha
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom